These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

337 related articles for article (PubMed ID: 23179002)

  • 1. Clinical outcome in patients with rheumatoid arthritis switched to tocilizumab after etanercept or infliximab failure.
    Wakabayashi H; Hasegawa M; Nishioka Y; Minami Y; Nishioka K; Sudo A
    Clin Rheumatol; 2013 Feb; 32(2):253-9. PubMed ID: 23179002
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Which subgroup of rheumatoid arthritis patients benefits from switching to tocilizumab versus etanercept after previous infliximab failure? A retrospective study.
    Wakabayashi H; Hasegawa M; Nishioka Y; Sudo A; Nishioka K
    Mod Rheumatol; 2012 Feb; 22(1):116-21. PubMed ID: 21710357
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A randomized comparative effectiveness study of oral triple therapy versus etanercept plus methotrexate in early aggressive rheumatoid arthritis: the treatment of Early Aggressive Rheumatoid Arthritis Trial.
    Moreland LW; O'Dell JR; Paulus HE; Curtis JR; Bathon JM; St Clair EW; Bridges SL; Zhang J; McVie T; Howard G; van der Heijde D; Cofield SS;
    Arthritis Rheum; 2012 Sep; 64(9):2824-35. PubMed ID: 22508468
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Insights into the efficacy of golimumab plus methotrexate in patients with active rheumatoid arthritis who discontinued prior anti-tumour necrosis factor therapy: post-hoc analyses from the GO-AFTER study.
    Smolen JS; Kay J; Matteson EL; Landewé R; Hsia EC; Xu S; Zhou Y; Doyle MK
    Ann Rheum Dis; 2014 Oct; 73(10):1811-8. PubMed ID: 23897769
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of the response to infliximab or etanercept monotherapy with the response to cotherapy with methotrexate or another disease-modifying antirheumatic drug in patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register.
    Hyrich KL; Symmons DP; Watson KD; Silman AJ;
    Arthritis Rheum; 2006 Jun; 54(6):1786-94. PubMed ID: 16736520
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical impact of switching from infliximab to etanercept in patients with rheumatoid arthritis.
    Laas K; Peltomaa R; Kautiainen H; Leirisalo-Repo M
    Clin Rheumatol; 2008 Jul; 27(7):927-32. PubMed ID: 18414967
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of biologic agents with and without concomitant methotrexate and at reduced doses in older rheumatoid arthritis patients.
    Zhang J; Xie F; Delzell E; Yun H; Lewis JD; Haynes K; Chen L; Beukelman T; Saag KG; Curtis JR
    Arthritis Care Res (Hoboken); 2015 May; 67(5):624-32. PubMed ID: 25370912
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preliminary evaluation in rheumatoid arthritis activity in patients treated with TNF-alpha blocker plus methotrexate versus methotrexate or leflunomide alone.
    Wisłowska M; Jakubicz D
    Rheumatol Int; 2007 May; 27(7):641-7. PubMed ID: 17235556
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative efficacy of biologics as monotherapy and in combination with methotrexate on patient reported outcomes (PROs) in rheumatoid arthritis patients with an inadequate response to conventional DMARDs--a systematic review and network meta-analysis.
    Jansen JP; Buckley F; Dejonckheere F; Ogale S
    Health Qual Life Outcomes; 2014 Jul; 12():102. PubMed ID: 24988902
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of concomitant DMARD therapy on adherence to treatment with etanercept and infliximab in rheumatoid arthritis. Results from a six-year observational study in southern Sweden.
    Kristensen LE; Saxne T; Nilsson JA; Geborek P
    Arthritis Res Ther; 2006; 8(6):R174. PubMed ID: 17121678
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness.
    Chen YF; Jobanputra P; Barton P; Jowett S; Bryan S; Clark W; Fry-Smith A; Burls A
    Health Technol Assess; 2006 Nov; 10(42):iii-iv, xi-xiii, 1-229. PubMed ID: 17049139
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Meta-analysis of the combination of TNF inhibitors plus MTX compared to MTX monotherapy, and the adjusted indirect comparison of TNF inhibitors in patients suffering from active rheumatoid arthritis.
    Lee YH; Woo JH; Rho YH; Choi SJ; Ji JD; Song GG
    Rheumatol Int; 2008 Apr; 28(6):553-9. PubMed ID: 17943257
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interleukin-6 receptor inhibition with tocilizumab and attainment of disease remission in rheumatoid arthritis: the role of acute-phase reactants.
    Smolen JS; Aletaha D
    Arthritis Rheum; 2011 Jan; 63(1):43-52. PubMed ID: 21204103
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [A comparison between the Simplified Disease Activity Index (SDAI) and the Disease Activity Score (DAS28) as measure of response to treatment in patients undergoing different therapeutic regimens].
    Cuomo G; Molinaro G; La Montagna G; Migliaresi S; Valentini G
    Reumatismo; 2006; 58(1):22-5. PubMed ID: 16639484
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Therapy of patients with rheumatoid arthritis: outcome of infliximab failures switched to etanercept.
    Buch MH; Bingham SJ; Bejarano V; Bryer D; White J; Reece R; Quinn M; Emery P
    Arthritis Rheum; 2007 Apr; 57(3):448-53. PubMed ID: 17394231
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predictors of remission with etanercept-methotrexate induction therapy and loss of remission with etanercept maintenance, reduction, or withdrawal in moderately active rheumatoid arthritis: results of the PRESERVE trial.
    Smolen JS; Szumski A; Koenig AS; Jones TV; Marshall L
    Arthritis Res Ther; 2018 Jan; 20(1):8. PubMed ID: 29338762
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The impact of conventional DMARD and biological therapies on CD4+ cell subsets in rheumatoid arthritis: a follow-up study.
    Szalay B; Vásárhelyi B; Cseh A; Tulassay T; Deák M; Kovács L; Balog A
    Clin Rheumatol; 2014 Feb; 33(2):175-85. PubMed ID: 23934385
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of etanercept 50 mg twice a week in patients with rheumatoid arthritis who had a suboptimal response to etanercept 50 mg once a week: results of a multicenter, randomized, double-blind, active drug-controlled study.
    Weinblatt ME; Schiff MH; Ruderman EM; Bingham CO; Li J; Louie J; Furst DE
    Arthritis Rheum; 2008 Jul; 58(7):1921-30. PubMed ID: 18576334
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Outcomes of switching anti-TNF drugs in rheumatoid arthritis--a study based on observational data from the Finnish Register of Biological Treatment (ROB-FIN).
    Virkki LM; Valleala H; Takakubo Y; Vuotila J; Relas H; Komulainen R; Koivuniemi R; Yli-Kerttula U; Mali M; Sihvonen S; Krogerus ML; Jukka E; Nyrhinen S; Konttinen YT; Nordström DC
    Clin Rheumatol; 2011 Nov; 30(11):1447-54. PubMed ID: 21644062
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The efficiency of switching from infliximab to etanercept and vice-versa in patients with rheumatoid arthritis.
    Cohen G; Courvoisier N; Cohen JD; Zaltni S; Sany J; Combe B
    Clin Exp Rheumatol; 2005; 23(6):795-800. PubMed ID: 16396697
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.